From Wikipedia, the free encyclopedia
Chemical compound
LY305
Legal status
2-Chloro-4-[[(1R ,2R )-2-hydroxy-2-methylcyclopentyl]amino]-3-methylbenzonitrile
CAS Number
PubChem
CID
ChemSpider
ChEMBL
Formula C 14 H 17 Cl N 2 O 2
Molar mass 280.75 g·mol−1 3D model (
JSmol )
CC1=C(C=CC(=C1Cl)C#N)N[C@@H]2CCC[C@@]2(C)O
InChI=1S/C14H17ClN2O/c1-9-11(6-5-10(8-16)13(9)15)17-12-4-3-7-14(12,2)18/h5-6,12,17-18H,3-4,7H2,1-2H3/t12-,14-/m1/s1
Key:CXFSVKGROITHRY-TZMCWYRMSA-N
LY305 is a
transdermally bioavailable
selective androgen receptor modulator (SARM) developed by
Eli Lilly for the treatment of
osteoporosis in men. Its chemical structure includes
N-arylhydroxyalkyl . A phase one trial found promising results.
[1]
[2]
[3]
See also
References
^ Krishnan, V.; Patel, N. J.; Mackrell, J. G.; Sweetana, S. A.; Bullock, H.; Ma, Y. L.; Waterhouse, T. H.; Yaden, B. C.; Henck, J.; Zeng, Q. Q.; Gavardinas, K.; Jadhav, P.; Saeed, A.; Garcia-Losada, P.; Robins, D. A.; Benson, C. T. (2018).
"Development of a selective androgen receptor modulator for transdermal use in hypogonadal patients" . Andrology . 6 (3): 455–464.
doi :
10.1111/andr.12479 .
^ Christiansen, Andrew R.; Lipshultz, Larry I.; Hotaling, James M.; Pastuszak, Alexander W. (March 2020).
"Selective androgen receptor modulators: the future of androgen therapy?" . Translational Andrology and Urology . 9 (Suppl 2): S135–S148.
doi :
10.21037/tau.2019.11.02 .
ISSN
2223-4683 .
PMC
7108998 .
PMID
32257854 .
^ Mohler ML, Sikdar A, Ponnusamy S, Hwang DJ, He Y, Miller DD, Narayanan R. An Overview of Next-Generation Androgen Receptor-Targeted Therapeutics in Development for the Treatment of Prostate Cancer. Int J Mol Sci . 2021 Feb 20;22(4):2124.
doi :
10.3390/ijms22042124
PMID
33672769